Cited by 333Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Open access

Curtis, Craig, Gamez, Jose E., Singh, Upinder, Sadowsky, Carl H., Villena, Teresa, Sabbagh, Marwan N., Beach, Thomas G., Duara, Ranjan, Fleisher, Adam S., Frey, Kirk A., Walker, Zuzana, Hunjan, Arvinder, Holmes, Clive, Escovar, Yavir M., Vera, Carla X., Agronin, Marc E., Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D., Sherwin, Paul F., Grachev, Igor D., Farrar, Gillian, Smith, Adrian P. L., Buckley, Christopher J., McLain, Richard, Salloway, Stephen·2015·JAMA Neurology

DOI 10.1001/jamaneurol.2014.4144

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. OBJECTIVE: To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to detect β-amyloid in the brain using neuropathologically determined neuritic plaque levels as the standard of truth. DESIGN, SETTING, AND PARTICIPANTS: Open-label multicenter imaging study that took place at dementia clinics, memory centers, and hospice centers in the United States and England from June 22, 2010, to November 23, 2011. Participants included terminally ill patients who were 55 years or older with a life expectancy of less than 1 year. INTERVENTIONS: Flutemetamol injection labeled with radioactive fluorine 18 (Vizamyl; GE Healthcare) administration followed by positron emission tomography imaging and subsequent brain donation. MAIN OUTCOMES AND MEASURES: Sensitivity and specificity of flutemetamol injection labeled with radioactive fluorine 18 positron emission tomography imaging for brain β-amyloid. Images were reviewed without and with computed tomography scans and classified as positive or negative for β-amyloid by 5 readers who were blind to patient information. In patients who died, neuropathologically determined neuritic plaque levels were used to confirm scan interpretations and determine sensitivity and specificity. RESULTS: Of 176 patients with evaluable images, 68 patients (38%) died during the study, were autopsied, and had neuritic plaque levels determined; 25 brains (37%) were β-amyloid negative; and 43 brains (63%) were β-amyloid positive. Imaging was performed a mean of 3.5 months (range, 0 to 13 months) before death. Sensitivity without computed tomography was 81% to 93% (median, 88%). Median specificity was 88%, with 4 of 5 of the readers having specificity greater than 80%. When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant. The area under the receiver operating curve was 0.90. There were no clinically meaningful findings in safety parameters. CONCLUSIONS AND RELEVANCE: This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population. In vivo detection of brain β-amyloid plaque density may increase diagnostic accuracy in cognitively impaired patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2014.4144

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citation
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Statistical Methods in Diagnostic Medicine
Zhou, X., Sun, J., Pennello, G. A., Obuchowski, N. A., & McClish, D. K. (2011) · Wiley series in probability and statistics · doi:10.1002/9780470906514 · Cited by 1,785
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Statistical Methods in Diagnostic Medicine
Zhou, X., Obuchowski, N. A., & McClish, D. K. (2002) · Wiley series in probability and statistics · doi:10.1002/9780470317082 · Cited by 1,166
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“39) [0-30] 8.”
Self-citation
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 101–200 of 333

Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 42
Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 44
Self-citation
Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 43
Current radiotracers to image neurodegenerative diseases
Tiepolt, S., Patt, M., Aghakhanyan, G., Meyer, P., Hesse, S., Barthel, H., & Sabri, O. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0070-7 · Cited by 46
Deep learning for Alzheimer's disease: Mapping large-scale histological tau protein for neuroimaging biomarker validation
Ushizima, D. M., Chen, Y., Alegro, M., Ovando, D., Eser, R. A., Lee, W., Poon, K., Shankar, A., Kantamneni, N., Satrawada, S., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118790 · Cited by 45
18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease.
Filippi, L., Chiaravalloti, A., Bagni, O., & Schillaci, O. (2018) · Europe PMC (PubMed Central) · Cited by 40
Alzheimer's disease: The use of contrast agents for magnetic resonance imaging to detect amyloid beta peptide inside the brain
Salerno, M., & Porqueras, D. S. D. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.018 · Cited by 41
Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care
Apostolova, L. G., Haider, J. M., Goukasian, N., Rabinovici, G. D., Chételat, G., Ringman, J. M., Kremen, S. A., Grill, J. D., Restrepo, L., Mendez, M. F., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.001 · Cited by 39
Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort
Reimand, J., Boon, B. D. C., Collij, L. E., Teunissen, C. E., Rozemüller, A. J. M., van Berckel, B. N. M., Scheltens, P., Ossenkoppele, R., & Bouwman, F. H. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51195 · Cited by 40
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria
Grundman, M., Johnson, K. A., Lu, M., Siderowf, A. D., Dell’Agnello, G., Arora, A., Skovronsky, D., Mintun, M. A., Pontecorvo, M. J., & for the 18F-AV-45-A17 Study Group (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000441139 · Cited by 38
Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: From biological biomarkers to clinical syndromes
Carandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36
Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada
Laforce, R. J., Rosa‐Neto, P., Soucy, J., Rabinovici, G. D., Dubois, B., & Gauthier, S. G. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.401 · Cited by 34
Evidence-based Interpretation of Amyloid-β PET Results
Bergeron, D., Ossenkoppele, R., & Laforce, R. J. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000239 · Cited by 33
A History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 37
Self-citation
The ADNI PET core at 20
Jagust, W. J., Koeppe, R. A., Rabinovici, G. D., Villemagne, V. L., Harrison, T. M., Landau, S. M., & Initiative, T. A. D. N. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14165 · Cited by 34
Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimer’s disease
DeBay, D. R., Reid, G. A., Macdonald, I. R., Mawko, G., Burrell, S., Martin, E. V., Bowen, C. V., & Darvesh, S. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.009 · Cited by 33
Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 35
Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease
Ni, R., Gillberg, P., Bogdanović, N., Viitanen, M. H., Myllykangas, L., Nennesmo, I., Långström, B., & Nordberg, A. K. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.006 · Cited by 32
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Gerth, J., Kumar, S., Upadhaya, A. R., Ghebremedhin, E., Arnim, C. A. F. V., Thal, D. R., & Walter, J. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.577 · Cited by 30
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0561-5 · Cited by 31
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous
Abrahamson, E. E., Kofler, J., Becker, C. R., Price, J. C., Newell, K. L., Ghetti, B. F., Murrell, J. R., McLean, C., López, O. L., Mathis, C. A., et al. (2021) · Brain · doi:10.1093/brain/awab434 · Cited by 28
Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
Ni, R., & Nitsch, R. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.751897 · Cited by 30
REVIEW ABOUT RADIOPHARMACEUTICALS: PREPARATION, RADIOACTIVITY, AND APPLICATIONS
Alsharif, S. M., ALANAZI, M., Alharthi, F. H. J., QANDIL, D., & Qushawy, M. K. E. (2020) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2020v12i3.37150 · Cited by 28
Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
Chincarini, A., Peira, E., Morbelli, S. D., Pardini, M., Bauckneht, M., Arbizu, J., Castelo-Branco, M. S., Büsing, K. A., de Mendonça, A., Didic, M., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101846 · Cited by 27
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 27
Vanillin Benzothiazole Derivative Reduces Cellular Reactive Oxygen Species and Detects Amyloid Fibrillar Aggregates in Alzheimer’s Disease Brain
Gharai, P. K., Khan, J., Mallesh, R., Garg, S., Saha, A., Ghosh, S., & Ghosh, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00771 · Cited by 28
Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease
DeBay, D. R., Reid, G. A., Pottie, I. R., Martin, E. V., Bowen, C. V., & Darvesh, S. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.01.005 · Cited by 27
Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition
Vacher, M., Porter, T., Villemagne, V. L., Milicic, L., Peretti, M., Fowler, C., Martins, R., Rainey-Smith, S., Ames, D., Masters, C. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53604-5 · Cited by 26
Parametric imaging and quantitative analysis of the PET amyloid ligand [ 18 F]flutemetamol
Heurling, K., Buckley, C. J., Laere, K. V., Vandenberghe, R. R., & Lubberink, M. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.07.037 · Cited by 26
Self-citation
Imaging Biomarkers in Alzheimer’s Disease: A Practical Guide for Clinicians
Sheikh‐Bahaei, N., Sajjadi, S. A., Manavaki, R., & Gillard, J. H. (2017) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-170013 · Cited by 29
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 26
Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01005-5 · Cited by 25
Self-citation
Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer’s disease
Xue, M., Initiative, A. D. N., Sun, F.-R., Ou, Y., Shen, X., Li, H., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Aging · doi:10.18632/aging.103211 · Cited by 25
Neuronal PET tracers for Alzheimer's disease.
Kumar, A. P., Singh, N., Nair, D. R., & Justin, A. (2021) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2021.11.093 · Cited by 15
Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia
Sheikh‐Bahaei, N., Sajjadi, S. A., & Pierce, A. L. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0484-z · Cited by 28
The brain cognitive reserve hypothesis: A review with emphasis on the contribution of nuclear medicine neuroimaging techniques
Giovacchini, G., Giovannini, E., Borsò, E., Lazzeri, P., Riondato, M., Leoncini, R., Duce, V., Mansi, L., & Ciarmiello, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28308 · Cited by 25
A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies
Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 25
Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression
Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 25
Self-citation
Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau
Chisholm, T. S., & Hunter, C. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00838 · Cited by 26
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
Collij, L. E., Farrar, G., García, D. V., Bader, I., Shekari, M., Lorenzini, L., Pemberton, H., Altomare, D., Pla, S., Loor, M., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1063598 · Cited by 22
Self-citation
Treatment of Mild Cognitive Impairment
Kelley, B. J. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0372-3 · Cited by 25
Thermolysis and radiofluorination of diaryliodonium salts derived from anilines
Linstad, E. J., Vāvere, A. L., Hu, B. X., Kempinger, J. J., Snyder, S. E., & DiMagno, S. G. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00253j · Cited by 23
Glitter in the Darkness? Nonfibrillar β-Amyloid Plaque Components Significantly Impact the β-Amyloid PET Signal in Mouse Models of Alzheimer Disease
Biechele, G., Monasor, L. S., Wind-Mark, K., Blume, T., Parhizkar, S., Arzberger, T., Sacher, C., Beyer, L., Eckenweber, F., Gildehaus, F., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261858 · Cited by 20
Benzothiazole-Based Therapeutics: FDA Insights and Clinical Advances
Cheekatla, S. R. (2025) · Chemistry · doi:10.3390/chemistry7040118 · Cited by 22
6-Methoxy-indanone derivatives as potential probes for β-amyloid plaques in Alzheimer's disease
Nan, D., Gan, C., Wang, C.-W., Qiao, J., Wang, X.-M., & Zhou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.069 · Cited by 21
Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases
Zhang, S., Dong, H., Bian, J., Li, D., & Liu, C. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.10.009 · Cited by 23
Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Rabinovici, G. D., Carrillo, M. C., Apgar, C., Gareen, I. F., Gutman, R., Hanna, L., Hillner, B. E., March, A., Romanoff, J., Siegel, B. A., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3490 · Cited by 20
Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls – A hybrid PET/MRI study
Tiepolt, S., Rullmann, M., Jochimsen, T. H., Gertz, H., Schroeter, M. L., Patt, M., Sabri, O., & Barthel, H. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109243 · Cited by 20
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
Leuzy, A., Lilja, J., Buckley, C. J., Ossenkoppele, R., Palmqvist, S., Battle, M. R., Farrar, G., Thal, D. R., Janelidze, S., Stomrud, E., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011031 · Cited by 20
Self-citation
The 2024 NIA-AA biological definition of Alzheimer’s disease: linking biomarkers to clinical practice
Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 22
New protein deposition tracers in the pipeline
Jovalekic, A., Koglin, N., Mueller, A., & Stephens, A. W. (2016) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-016-0015-3 · Cited by 19
Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration
Blazhenets, G., Frings, L., Ma, Y., Sörensen, A., Eidelberg, D., Wiltfang, J., Meyer, P. T., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000011521 · Cited by 21
(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
Tiepolt, S., Becker, G., Wilke, S., Cecchin, D., Rullmann, M., Meyer, P., Barthel, H., Hesse, S., Patt, M., Luthardt, J., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05029-w · Cited by 13
Binding adaptability of chemical ligands to polymorphic α-synuclein amyloid fibrils
Liu, K., Tao, Y., Zhao, Q., Xia, W., Li, X., Zhang, S., Yao, Y., Xiang, H., Han, C., Tan, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321633121 · Cited by 21
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 21
Review of triazole scaffolds for treatment and diagnosis of Alzheimer's disease
Li, Q., Qi, S., Liang, J., Tian, Y., He, S., Liao, Q., Xing, S., Han, L., & Chen, X. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110623 · Cited by 19
The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology
Tam, S., Wear, D., Morrone, C. D., & Yu, W. H. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16108 · Cited by 20
Antemortem-Postmortem Correlation of Florbetapir ( 18 F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ 42 but not Aβ 40
Beach, T. G., Maarouf, C. L., Intorcia, A. J., Sue, L. I., Serrano, G. E., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Roher, A. E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170762 · Cited by 18
Self-citation
Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?
Farrar, G., Molinuevo, J. L., & Zanette, M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04282-y · Cited by 17
Self-citation
Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population
Kim, H.-R., Jung, S.-H., Kim, J., Kang, S. H., Kang, S. H., Hwangbo, S., Kim, J. P., Kim, B., Kim, S., Kim, S., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00854-z · Cited by 18
Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer’s disease
Müller, E. G., Stokke, C., Stokmo, H. L., Edwin, T. H., Knapskog, A., & Revheim, M.-E. R. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-21-188 · Cited by 17
AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention
Meyer, P., McSweeney, M., Gonneaud, J., & Villeneuve, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.001 · Cited by 20
Translating amyloid PET of different radiotracers by a deep generative model for interchangeability
Kang, S. K., Choi, H., & Lee, J. S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117890 · Cited by 17
Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease
Jasiecki, J., Limon-Sztencel, A., Żuk, M., Chmara, M., Cysewski, D., Limon, J., & Wasąg, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-41578-3 · Cited by 17
Whole brain optoacoustic tomography reveals strain-specific regional beta-amyloid densities in Alzheimer’s disease amyloidosis modelsPreprint
Ni, R., Deán‐Ben, X. L., Kirschenbaum, D. S., Rudin, M., Chen, Z., Crimi, A., Voigt, F. F., Nilsson, K. P. R., Helmchen, F., Nitsch, R. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.25.964064 · Cited by 17
Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer’s disease based on the A/T(N) research framework
Wang, Y., Zhang, Y., & Yu, E. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108071 · Cited by 16
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
Mastenbroek, S. E., Sala, A., García, D. V., Shekari, M., Salvadó, G., Lorenzini, L., Pieperhoff, L., Wink, A. M., Alves, I. L., Wolz, R., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209419 · Cited by 16
Self-citation
Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer’s Disease Affected Brain
Okumura, Y., Maya, Y., Onishi, T., Shoyama, Y., Izawa, A., Nakamura, D., Tanifuji, S., Tanaka, A., Arano, Y., & Matsumoto, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00064 · Cited by 16
Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer’s disease
Selvan, S. T., Ravichandar, R., Ghosh, K. K., Mohan, A., Mahalakshmi, P., Gulyás, B. Z., & Padmanabhan, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213659 · Cited by 16
Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Giacomucci, G., Mazzeo, S., Bagnoli, S., Casini, M., Padiglioni, S., Polito, C., Berti, V., Balestrini, J., Ferrari, C., Lombardi, G., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010047 · Cited by 16
High Correlation of Static First-Minute-Frame (FMF) PET Imaging after 18F-Labeled Amyloid Tracer Injection with [18F]FDG PET Imaging
Seiffert, A. P., Gómez‐Grande, A., Villarejo‐Galende, A., González‐Sánchez, M., Bueno, H., Aguilera, E. J. G., & González, P. S. (2021) · Sensors · doi:10.3390/s21155182 · Cited by 15
Eye-Tracking Metrics for Figure-Copying Processes in Early- vs. Late-Onset Alzheimer's Disease
Kim, K. W., Choi, J. D., Chin, J., Lee, B. H., & Na, D. L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844341 · Cited by 16
Synthesis and evaluation of copper-64 labeled benzofuran derivatives targeting β-amyloid aggregates
Watanabe, H., Kawasaki, A., Sano, K., Ono, M., & Saji, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.001 · Cited by 15
Molecular imaging: What is right and what is an illusion?
Klunk, W. E. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.004 · Cited by 15
Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks
Zhang, Y., Ghose, U., Buckley, N. J., Engelborghs, S., Sleegers, K., Frisoni, G. B., Wallin, A., Lleó, A., Popp, J., Martínez‐Lage, P., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1040001 · Cited by 16
Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome
Kurz, C., Carli, L., Guersel, S., Schrurs, I., Jethwa, A., Carboni, M., Bittner, T., Hortsch, S., Keeser, D., Brendel, M., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02013-z · Cited by 16
Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers
Miki, T., Shimada, H., Kim, J., Yamamoto, Y., Sugino, M., Kowa, H., Heurling, K., Zanette, M., Sherwin, P. F., & Senda, M. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1154-7 · Cited by 15
Self-citation
The Role of Amyloid PET in Diagnosing Possible Transmissible Cerebral Amyloid Angiopathy in Young Adults with a History of Neurosurgery: A Case Series
Michiels, L., Weehaeghe, D. V., Vandenberghe, R. R., Demeestere, J., Laere, K. V., & Lemmens, R. (2021) · Cerebrovascular Diseases · doi:10.1159/000514139 · Cited by 14
Self-citation
Clinical Usefulness of 18F-FC119S Positron-Emission Tomography as an Auxiliary Diagnostic Method for Dementia: An Open-Label, Single-Dose, Evaluator-Blind Clinical Trial
Lee, I., Na, H. R., Byun, B. H., Lim, I., Kim, B. I., Choi, C. W., Ko, I. O., Lee, K. C., Kim, K. M., Park, S. Y., et al. (2020) · Journal of Clinical Neurology · doi:10.3988/jcn.2020.16.1.131 · Cited by 13
Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment
Baik, K., Jeon, S., Park, M., Lee, Y., Lee, P. H., Sohn, Y. H., & Ye, B. S. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0207 · Cited by 13
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenigro, P. H., Siemers, E., Sink, K. M., Shaw, L. M. J., Hansen, C. T., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70013 · Cited by 15
Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation
Wright, J. P., Goodman, J. R., Lin, Y., Lieberman, B. P., Clemens, J., Gomez, L. F., Liang, Q., Hoye, A. T., Pontecorvo, M. J., & Conway, K. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05822-9 · Cited by 13
β‐Amyloid may accumulate in the human brain after focal bacterial infection: An 18F‐flutemetamol positron emission tomography study
Rogne, A. G., Müller, E. G., Udnæs, E., Sigurðardóttir, S., Raudeberg, R., Connelly, J. P., Revheim, M.-E. R., Hassel, B., & Dahlberg, D. (2020) · European Journal of Neurology · doi:10.1111/ene.14622 · Cited by 13
Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases
Serrano, G. E., Intorcia, A. J., Carew, J., Chiarolanza, G., Hidalgo, J. A., Sue, L. I., Dugger, B. N., Saxon‐LaBelle, M., Filon, J. R., Scroggins, A., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000235 · Cited by 13
Self-citation
Update on the Cognitive Presentations of iNPH for Clinicians
Langheinrich, T., Chen, C., & Thomas, O. M. T. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.894617 · Cited by 11
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 14
Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study
Thomas, J., Ooms, S. J., Mentink, L. J., Booij, J., Rikkert, M. G. M. O., Overeem, S., Kessels, R. P. C., & Claassen, J. A. H. R. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00668-5 · Cited by 13
Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools
Landrieu, I., Dupré, E., Sinnaeve, D., Hajjar, L. E., & Smet‐Nocca, C. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.886382 · Cited by 12
Unraveling Alzheimer’s complexity with a distinct Aβ42 fibril type and specific AV-45 binding
Zhao, Q., Tao, Y., Yao, Y., Liu, K., Lv, S., Cui, B., Xiao, W., Cao, T., Li, W., Gao, F., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01921-4 · Cited by 14
No difference in retinal fluorescence after oral curcumin intake in amyloid‐proven AD cases compared to controls
den Haan, J., de Ruyter, F. J. H., Lochocki, B., Kroon, M. A. G. M., Kemper, E. M., Teunissen, C. E., van Berckel, B. N. M., Scheltens, P., Hoozemans, J. J. M., van de Kreeke, A., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12347 · Cited by 11
PET Radioligands for Imaging of Tau Pathology: Current Status
Choe, Y. S., & Lee, K.-H. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-015-0374-9 · Cited by 11
Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?
Paghera, B., Altomare, D., Peli, A., Morbelli, S. D., Buschiazzo, A., Bauckneht, M., Giubbini, R., Rodella, C. A., Camoni, L., Boccardi, M., et al. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03124-8 · Cited by 12
Global experience in brain amyloid imaging
Filippi, L., & Schillaci, O. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.004 · Cited by 11
Squaryl Molecular Metaphors – Application to Rational Drug Design and Imaging Agents
Kitson, S. L. (2017) · Journal of Diagnostic Imaging in Therapy · doi:10.17229/jdit.2017-0503-029 · Cited by 9
Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer’s disease
Thientunyakit, T., Thongpraparn, T., Sethanandha, C., Yamada, T., Kimura, Y., Muangpaisan, W., & Ishii, K. (2021) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01132-6 · Cited by 11
Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology
Martersteck, A., Ayala, I., Ohm, D. T., Spencer, C., Coventry, C., Weintraub, S., Bigio, E. H., Mesulam, M. M., Geula, C., & Rogalski, E. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01412-w · Cited by 9
Post‐ M ortem evaluation of amyloid‐dopamine terminal positron emission tomography dementia classifications
Albin, R. L., Fisher‐Hubbard, A., Shanmugasundaram, K., Koeppe, R. A., Burke, J. F., Camelo-Piragua, S. I., Lieberman, A. P., Giordani, B., & Frey, K. A. (2015) · Annals of Neurology · doi:10.1002/ana.24481 · Cited by 9
Self-citation
Clinical impact and diagnostic accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (PET/CT) brain imaging in patients with cognitive impairment: a tertiary centre experience in the UK
Motara, H., Olusoga, T., Russell, G., Jamieson, S., Ahmed, S., Brindle, N., Pillai, A., Scarsbrook, A. F., Patel, C. N., & Chowdhury, F. U. (2016) · Clinical Radiology · doi:10.1016/j.crad.2016.08.003 · Cited by 9
Identifying a subtype of Alzheimer’s disease characterised by predominant right focal cortical atrophy
Kim, K. W., Park, S., Jo, H., Cho, S. H., Kim, S. J., Kim, Y., Jang, H., Na, D. L., Seo, S. W., & Kim, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-64180-4 · Cited by 10
Separation of β-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis.
Heurling, K., Buckley, C. J., Vandenberghe, R. R., Laere, K. V., & Lubberink, M. (2015) · Europe PMC (PubMed Central) · Cited by 9
Self-citation

Authors: Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., Walker, Z., Hunjan, A., Holmes, C., Escovar, Y. M., Vera, C. X., Agronin, M. E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R., Ikonomovic, M. D., Sherwin, P. F., Grachev, I. D., Farrar, G., Smith, A. P. L., Buckley, C. J., McLain, R., & Salloway, S.
Affiliations: Compass Research (US)
Galiz Research, Miami Springs, Florida
Geriatric Solutions, Las Vegas, Nevada
Nova Southeastern University (US)
Premiere Research Institute (US)
Banner Sun Health Research Institute (US)
Mount Sinai Medical Center (US)
University of California San Diego (US)
University of Michigan (US)
University College London (GB)
North Essex Partnership University NHS Foundation Trust, Essex, England
University of Southampton (GB)
VERITAS Research, Miami Lakes, Florida
University of Miami (US)
Memory Enhancement Center of America (US)
Michigan State University (US)
Kennington Health Centre, Oxford, England
Barrow Neurological Institute (US)
Universitair Ziekenhuis Leuven (BE)
Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania
Medical Affairs, GE Healthcare–Life Sciences, Princeton, New Jersey
Novartis (United States) (US)
Amersham Hospital (GB)
PFP Statistical Consulting LLC, Livonia, Michigan
Brown University (US)
ORCID: Sabbagh, Marwan N.
Beach, Thomas G.
Duara, Ranjan
Fleisher, Adam S.
Frey, Kirk A.
Walker, Zuzana
Holmes, Clive
Agronin, Marc E.
Ross, Joel
Bozoki, Andrea
Shi, Jiong
Vandenberghe, Rik
Sherwin, Paul F.
Smith, Adrian P. L.
Buckley, Christopher J.
Salloway, Stephen
Venue: JAMA Neurology
Publisher: American Medical Association (AMA)
Published: 2015-03-01
Volume: 72
Issue: 3
Pages: 287
ISSN: 2168-6149 (ISSN-L)
DOI: 10.1001/jamaneurol.2014.4144
OpenAlex: W2164443763
Cited by: 332
References: 30
Citations by year: 2026: 17 · 2025: 41 · 2024: 26 · 2023: 20 · 2022: 29 · 2021: 34 · 2020: 36 · 2019: 29 · 2018: 20 · 2017: 24 · 2016: 33 · 2015: 22
FWCI: 26.77
Type: journal article
Language: en
Open access: green
lirias.kuleuven.be
Licence: other-oa
Locations: JAMA Neurology (publishedVersion)
PubMed (publishedVersion)
Lirias (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: Alzheimer's disease, sensitivity and specificity, dying patients, brain donation, dementia diagnosis
MeSH terms: Aged, Aged, 80 and over, Aniline Compounds, Female, Fluorine Radioisotopes, Humans, Male, Middle Aged, Single-Blind Method, Positron-Emission Tomography, Benzothiazoles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks